Overall, these data suggest that MTR-OralGem treatment yields robust immunostimulatory effects in the lung TME, accompanied by an upregulation of PD-1/PD-L-1 interactions between T effectors and tumor cells. This evidence concerns the gene PDCD1 and neoplasm.